By Kai-Jye Lou, Senior Writer
Taking a BET on hedgehog
Stanford University School of Medicine researchers have uncovered an interplay between BET
bromodomain proteins and the hedgehog pathway that opens up
additional oncology real estate for BET inhibitors.1 The inhibitors
could be among the first molecules to work in hedgehog-driven cancers that no
longer respond to smoothened inhibitors or other pathway modulators.